Ab Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

13.85EUR
28 Aug 2015
Change (% chg)

€0.45 (+3.36%)
Prev Close
€13.40
Open
€13.65
Day's High
€14.30
Day's Low
€13.57
Volume
62,367
Avg. Vol
68,269
52-wk High
€18.93
52-wk Low
€7.16

ABS.PA

Chart for ABS.PA

About

AB Science SA, also known as AB Science, is a France-based pharmaceutical company specialized in the research, discovery, development and marketing of protein kinase inhibitors (PKIs). It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer,... (more)

Overall

Beta: 1.40
Market Cap(Mil.): €469.51
Shares Outstanding(Mil.): 33.90
Dividend: --
Yield (%): --

Financials

  ABS.PA Industry Sector
P/E (TTM): -- 35.90 36.13
EPS (TTM): -0.49 -- --
ROI: -66.66 15.37 14.83
ROE: -- 15.94 15.69
Search Stocks

BRIEF-AB Science announces successful non futility test for masitinib in progressive forms of multiple sclerosis

* Announces successful non futility test for masitinib in progressive forms of multiple sclerosis

23 Jul 2015

BRIEF-Ab Science receives recommendation to continue phase III for masitinib in c-Kit mutated metastatic melanoma

* Announces successful futility test for masitinib in c-Kit mutated metastatic melanoma

21 Jul 2015

BRIEF-Ab Science initiates new phase of study with masitinib

* Announces initiation of an adaptive design phase 2/3 study with masitinib in patients with refractory metastatic ovarian cancer Source text for Eikon: Further company coverage: (Gdynia Newsroom)

15 Jul 2015

BRIEF-Ab Science announces update on masitinib program

* Announces update on phase 1/2 program with masitinib in solid tumors

25 Jun 2015

BRIEF-Ab Science Mastinib in peripheral t-cell lymphoma accelerated into phase 3

* Phase 2 with Masitinib in peripheral T-cell lymphoma accelerated into phase 3

27 May 2015

BRIEF-AB Science announces new U.S. patent for masitinib in treatment of asthma

* Announces issuance of a new U.S. patent for masitinib in the treatment of severe persistent asthma

25 May 2015

BRIEF-Ab Science FY net loss widens to 16.1 million euros

* FY net loss of 16.1 million euros ($18.0 million) versus loss of 14.6 million euros year ago

30 Apr 2015

BRIEF-Results of Ab Science's Masitinib treatment to be published in Annals of Oncology

* The phase III results of the Masitinib treatment of advanced pancreatic cancer to be published in Annals of Oncology Source text for Eikon: Further company coverage: (Gdynia Newsroom)

09 Apr 2015

BRIEF-Ab Science DSMB recommends continuation of phase II Masitinib study

* Announces that DSMB recommends the continuation of phase 2 study assessing Masitinib in relapsing head and neck cancer

30 Mar 2015

BRIEF-Ab Science's Masitinib receives orphan drug designation for amyotrophic lateral sclerosis from FDA

* Masitinib receives orphan drug designation for amyotrophic lateral sclerosis from FDA

20 Mar 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks